NEW YORK (Reuters) - Merck & Co, which plans to buy rival drugmaker Schering-Plough Corp later this year, reported lower-than-expected sales and earnings that it attributed to the global economic slowdown.
NEW YORK (Reuters) - Merck & Co, which plans to buy rival drugmaker Schering-Plough Corp later this year, reported lower-than-expected sales and earnings that it attributed to the global economic slowdown.
